Literature DB >> 21110120

Is the dopamine D3 receptor mRNA on blood lymphocytes help to for identification and subtyping of schizophrenia?

M Urhan-Kucuk1, M E Erdal, M E Ozen, S Kul, H Herken.   

Abstract

Schizophrenia is one of the neuropathological disorders, which are associated with dopamine and its receptors. In recent years, it has been shown that mRNA of D3, D4 and D5 dopamine receptor (DRD3, DRD4, DRD5) subtypes is expressed in human peripheral blood lymphocytes (PBL). A total 55 schizophrenic patients and 51 healthy subjects were included in the study to investigate the levels of DRD3 mRNA in PBL of schizophrenic patients and whether DRD3 mRNA level in PBL can serve as peripheral marker for schizophrenia. RNA was isolated from lymphocytes of both groups and reverse transcriptase polymerase chain reaction (RT-PCR) was performed for DRD3 mRNA. We found a significant difference in PBL DRD3 mRNA levels among schizophrenia subtypes (P=0.030) while no difference was detected between control subjects and schizophrenics. We concluded that the levels of DRD3 mRNA can help understanding and severity of clinical manifestations in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21110120     DOI: 10.1007/s11033-010-0396-4

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  22 in total

Review 1.  The D3 dopamine receptor: neurobiology and potential clinical relevance.

Authors:  B Levant
Journal:  Pharmacol Rev       Date:  1997-09       Impact factor: 25.468

Review 2.  The peripheral dopaminergic system: morphological analysis, functional and clinical applications.

Authors:  F Amenta; A Ricci; S K Tayebati; D Zaccheo
Journal:  Ital J Anat Embryol       Date:  2002 Jul-Sep

3.  Dopamine D1-like receptor subtypes in human peripheral blood lymphocytes.

Authors:  A Ricci; E Bronzetti; F Mignini; S K Tayebati; D Zaccheo; F Amenta
Journal:  J Neuroimmunol       Date:  1999-05-03       Impact factor: 3.478

4.  Migraine patients show an increased density of dopamine D3 and D4 receptors on lymphocytes.

Authors:  P Barbanti; G Fabbrini; A Ricci; M P Pascali; E Bronzetti; F Amenta; G L Lenzi; R Cerbo
Journal:  Cephalalgia       Date:  2000-02       Impact factor: 6.292

5.  Decreased levels of dopamine D3 receptor mRNA in schizophrenic and bipolar patients.

Authors:  Matthias Vogel; Silvia Pfeifer; Rainer T Schaub; Hans-Jörgen Grabe; Sven Barnow; Harald J Freyberger; Ingolf Cascorbi
Journal:  Neuropsychobiology       Date:  2004       Impact factor: 2.328

6.  Dopamine receptor D3 mRNA expression in human lymphocytes is negatively correlated with the personality trait of persistence.

Authors:  Christoph Czermak; Michael Lehofer; Helmut Renger; Elke M Wagner; Leonidas Lemonis; Alfred Rohrhofer; Konrad Schauenstein; Peter M Liebmann
Journal:  J Neuroimmunol       Date:  2004-05       Impact factor: 3.478

Review 7.  Molecular attributes of dopamine receptors: new potential for antipsychotic drug development.

Authors:  D S Hartman; O Civelli
Journal:  Ann Med       Date:  1996-06       Impact factor: 4.709

8.  Functional polymorphism of -141C Ins/Del in the dopamine D2 receptor gene promoter and schizophrenia.

Authors:  K Ohara; M Nagai; K Tani; Y Nakamura; A Ino; K Ohara
Journal:  Psychiatry Res       Date:  1998-11-16       Impact factor: 3.222

9.  Reduced dopamine D4 receptor mRNA expression in lymphocytes of long-term abstinent alcohol and heroin addicts.

Authors:  Christoph Czermak; Michael Lehofer; Elke M Wagner; Barbara Prietl; Leonidas Lemonis; Alfred Rohrhofer; Konrad Schauenstein; Peter M Liebmann
Journal:  Addiction       Date:  2004-02       Impact factor: 6.526

10.  Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism.

Authors:  Bernard Lerer; Ronnen H Segman; Heiner Fangerau; Ann K Daly; Vincenzo S Basile; Roberto Cavallaro; Harald N Aschauer; Robin G McCreadie; Stephanie Ohlraun; Nicol Ferrier; Mario Masellis; Massimiliano Verga; Joachim Scharfetter; Marcella Rietschel; Roger Lovlie; Uriel Heresco Levy; Herbert Y Meltzer; James L Kennedy; Vidar M Steen; Fabio Macciardi
Journal:  Neuropsychopharmacology       Date:  2002-07       Impact factor: 7.853

View more
  5 in total

Review 1.  Adaptive Immunity in Schizophrenia: Functional Implications of T Cells in the Etiology, Course and Treatment.

Authors:  Monojit Debnath
Journal:  J Neuroimmune Pharmacol       Date:  2015-07-11       Impact factor: 4.147

Review 2.  Immunomodulatory Effects Mediated by Dopamine.

Authors:  Rodrigo Arreola; Samantha Alvarez-Herrera; Gilberto Pérez-Sánchez; Enrique Becerril-Villanueva; Carlos Cruz-Fuentes; Enrique Octavio Flores-Gutierrez; María Eugenia Garcés-Alvarez; Dora Luz de la Cruz-Aguilera; Emilio Medina-Rivero; Gabriela Hurtado-Alvarado; Saray Quintero-Fabián; Lenin Pavón
Journal:  J Immunol Res       Date:  2016-10-04       Impact factor: 4.818

3.  The mRNA Expression Status of Dopamine Receptor D2, Dopamine Receptor D3 and DARPP-32 in T Lymphocytes of Patients with Early Psychosis.

Authors:  Yin Cui; Vishwanath Prabhu; Thong Ba Nguyen; Binod Kumar Yadav; Young-Chul Chung
Journal:  Int J Mol Sci       Date:  2015-11-06       Impact factor: 5.923

4.  Peripheral Immune Cell Populations Associated with Cognitive Deficits and Negative Symptoms of Treatment-Resistant Schizophrenia.

Authors:  Emilio Fernandez-Egea; Petra E Vértes; Shaun M Flint; Lorinda Turner; Syed Mustafa; Alex Hatton; Kenneth G C Smith; Paul A Lyons; Edward T Bullmore
Journal:  PLoS One       Date:  2016-05-31       Impact factor: 3.240

Review 5.  The role of dopamine receptors in lymphocytes and their changes in schizophrenia.

Authors:  M A Penedo; T Rivera-Baltanás; D Pérez-Rodríguez; J Allen; A Borrajo; D Alonso-Crespo; C Fernández-Pereira; M Nieto-Araujo; S Ramos-García; C Barreiro-Villar; H J Caruncho; J M Olivares; R C Agís-Balboa
Journal:  Brain Behav Immun Health       Date:  2021-01-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.